Absci (ABSI) Return on Sales (2020 - 2026)

Absci (ABSI) posted Return on Sales of 1.38% for Q1 2026, down 202.7% sequentially from 0.45% in Q4 2025, and down 115.0% YoY from 9.18% in Q1 2025.

Absci (ABSI) Return on Sales (2020 - 2026) Analysis & Trends

Absci has reported Return on Sales for 7 years, with the latest figure at 1.38% in Q1 2026.

Quarterly Return on Sales fell 115.0% year-over-year to 1.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.65% (down 42.0% YoY) and the FY2025 annual result came in at 0.41%, down 18.0% from the prior year.
Return on Sales retreated to 1.38% in Q1 2026 per ABSI's latest filing, from 0.45% in the prior quarter.
Over five years, Return on Sales peaked at 0.12% in Q2 2023 and troughed at 1.38% in Q1 2026.
A 5-year average of 0.48% and a median of 0.44% in 2024 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2026: Return on Sales surged 84 bps in 2022, then sank 115 bps in 2026.
Over 5 years, Return on Sales stood at 0.57% in 2022, then declined by 21 bps to 0.7% in 2023, then jumped by 37 bps to 0.44% in 2024, then retreated by 4 bps to 0.45% in 2025, then slumped by 203 bps to 1.38% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 1.38%, 0.45%, and 0.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Absci	1.58 Bn	1.37 Bn	-	-1.04%

Download Data